The Administrative Core (Core A) will continue to provide oversight of all SPORE activities including the Projects, Cores, Developmental Research Program, Career Development Program, and activities carried out under the auspices of SPORE supplements. The Core ensures compliance with all local, federal and NCI regulations and requirements. The Core is responsible for communication and consultation with NCI personnel in preparation of all required reports and publications. The Core is responsible for all fiscal and budgetary functions. The Core organizes all meetings including the monthly SPORE investigators meeting, meetings with the Executive Committee as well as the Internal and External Scientific Advisory Boards. The Core establishes and monitors policies for the recruitment of women and minorities, both as participants on SPORE trials, and also as SPORE investigators. The Core coordinates travel of SPORE investigators to all NCI-sponsored SPORE meetings. The Core interacts with the Developmental Research Program and the Career Development Program to ensure smooth functioning of these SPORE components. The Core coordinates activities with the University of Pittsburgh Cancer Institute to avoid redundancy and ensure that joint activities between the UPCI Head and Neck Cancer Program and the Head and Neck Cancer SPORE are carried out efficiently and that the programs are complementary and synergistic. The Administrative Core interacts with the NCI Program office to ensure that the SPORE guidelines are followed and that the mandate of the SPORE program is carried out. The Core also facilitates collaborations with the UPCI Lung Cancer SPORE and newly funded Skin SPORE as well as the Head and Neck Cancer SPORE programs at other institutions. In the prior funding period, the Core played a key role in changing project directions, developing new projects, and initiating collaborations with input from both the Internal and External Advisory Boards. These decisions led to the new projects proposed in this renewal application.

Public Health Relevance

Coordination of the projects, cores and programs in this SPORE will be overseen by this Administrative Core. This will include scheduling of monthly meetings and facilitation of interactions with members of the lAB and EAB. Oversight activities will include monitoring of progress for each project, core, DRP pilot, and CDP candidate. These functions are critical for the operations of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-09
Application #
8541590
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$205,005
Indirect Cost
$86,637
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Nikiforova, Marina N; Mercurio, Stephanie; Wald, Abigail I et al. (2018) Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 124:1682-1690
Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2018) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res 24:659-673
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72
Lee, Yoon Se; Johnson, Daniel E; Grandis, Jennifer R (2018) An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs :1-17
Johnson, Daniel E; O'Keefe, Rachel A; Grandis, Jennifer R (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234-248

Showing the most recent 10 out of 310 publications